Egetis Therapeutics AB (OSTO:EGTX) FFO


OSTO:EGTX Egetis Therapeutics AB OSTO:EGTX
65 GF Score
Price kr6.07
GF Value kr5.56
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:EGTX
65GF Score
Egetis Therapeutics AB OSTO:EGTX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (OSTO:EGTX) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.07 is trading 9.2% above its estimated GF Value™ of kr5.56. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for OSTO:EGTX:

  • FFO:
  • GF Value™: kr5.56 vs. price of kr6.07 (9.2% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the OSTO:EGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USA0ABW:UKP0F:Germany
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
65GF Score

Get the complete analysis for OSTO:EGTX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.07
Price
kr5.56
GF Value